Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope

Sizheng Steven Zhao; Stephanie R Harrison; Antoni Chan; Nick Clarke; Charlotte Davis; Joe Eddison; William J Gregory; Gareth T Jones; Helena Marzo-Ortega; Daniel J Murphy; Virinderjit Sandhu; Raj Sengupta; Stefan Siebert; Ben Thompson; Dale Webb; Max Yates; Karl Gaffney

doi:10.1093/rap/rkad039

Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope

Sizheng Steven Zhao^* (Corresponding Author), Stephanie R Harrison, Antoni Chan, Nick Clarke, Charlotte Davis, Joe Eddison, William J Gregory, Gareth T Jones, Helena Marzo-Ortega, Daniel J Murphy, Virinderjit Sandhu, Raj Sengupta, Stefan Siebert, Ben Thompson, Dale Webb, Max Yates, Karl Gaffney

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

1 Citation (Scopus)

Abstract

Pharmacological management has advanced considerably since the 2015 British Society for Rheumatology axial spondyloarthritis (axSpA) guideline to incorporate new classes of biologic DMARDs (bDMARDs, including biosimilars), targeted synthetic DMARDs (tsDMARDs) and treatment strategies such as drug tapering. The aim of this guideline is to provide an evidence-based update on pharmacological management of adults with axSpA (including AS and non-radiographic axSpA) using b/tsDMARDs. This guideline is aimed at health-care professionals in the UK who care directly for people with axSpA, including rheumatologists, rheumatology specialist nurses, allied health professionals, rheumatology specialty trainees and pharmacists; people living with axSpA; and other stakeholders, such as patient organizations and charities.

Original language	English
Article number	rkad039
Journal	Rheumatology advances in practice
Volume	7
Issue number	2
DOIs	https://doi.org/10.1093/rap/rkad039
Publication status	Published - 15 May 2023

Bibliographical note

Funding: This work was supported by the British Society for Rheumatology.

Acknowledgements: S.S.Z. is supported by a National Institute for Health Research (NIHR) Clinical Lectureship and works in centres supported by Versus Arthritis (grant numbers 21173, 21754 and 21755). H.M.-O. is Chair and Trustee of the British Society for Spondyloarthritis (BRITSpA). H.M.-O. is supported by the NIHR Leeds Biomedical Research Centre (LBRC). The views expressed are those of the authors and not necessarily those of the (UK) National Health Service (NHS), the NIHR or the (UK) Department of Health.

© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Data Availability Statement

No new data were generated in support of this work.

Keywords

Axial spondyloarthritis
AS
Biologic
Biosimilar
IL17
JAK inhibitor
treat-to-target
switching
tapering

Access to Document

10.1093/rap/rkad039Licence: CC BY

Zhao_etal_RAP_Treatment_of_Axial_VOR
VC The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Final published version, 2.28 MBLicence: CC BY

Cite this

Zhao, S. S., Harrison, S. R., Chan, A., Clarke, N., Davis, C., Eddison, J., Gregory, W. J., Jones, G. T., Marzo-Ortega, H., Murphy, D. J., Sandhu, V., Sengupta, R., Siebert, S., Thompson, B., Webb, D., Yates, M., & Gaffney, K. (2023). Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. Rheumatology advances in practice, 7(2), Article rkad039. https://doi.org/10.1093/rap/rkad039

Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. / Zhao, Sizheng Steven (Corresponding Author); Harrison, Stephanie R; Chan, Antoni et al.
In: Rheumatology advances in practice, Vol. 7, No. 2, rkad039, 15.05.2023.

Research output: Contribution to journal › Review article › peer-review

Zhao, SS, Harrison, SR, Chan, A, Clarke, N, Davis, C, Eddison, J, Gregory, WJ, Jones, GT, Marzo-Ortega, H, Murphy, DJ, Sandhu, V, Sengupta, R, Siebert, S, Thompson, B, Webb, D, Yates, M & Gaffney, K 2023, 'Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope', Rheumatology advances in practice, vol. 7, no. 2, rkad039. https://doi.org/10.1093/rap/rkad039

@article{7d5c1d866f3c418cb30bd7c158308d6a,

title = "Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope",

abstract = "Pharmacological management has advanced considerably since the 2015 British Society for Rheumatology axial spondyloarthritis (axSpA) guideline to incorporate new classes of biologic DMARDs (bDMARDs, including biosimilars), targeted synthetic DMARDs (tsDMARDs) and treatment strategies such as drug tapering. The aim of this guideline is to provide an evidence-based update on pharmacological management of adults with axSpA (including AS and non-radiographic axSpA) using b/tsDMARDs. This guideline is aimed at health-care professionals in the UK who care directly for people with axSpA, including rheumatologists, rheumatology specialist nurses, allied health professionals, rheumatology specialty trainees and pharmacists; people living with axSpA; and other stakeholders, such as patient organizations and charities.",

keywords = "Axial spondyloarthritis, AS, Biologic, Biosimilar, IL17, JAK inhibitor, treat-to-target, switching, tapering",

author = "Zhao, {Sizheng Steven} and Harrison, {Stephanie R} and Antoni Chan and Nick Clarke and Charlotte Davis and Joe Eddison and Gregory, {William J} and Jones, {Gareth T} and Helena Marzo-Ortega and Murphy, {Daniel J} and Virinderjit Sandhu and Raj Sengupta and Stefan Siebert and Ben Thompson and Dale Webb and Max Yates and Karl Gaffney",

note = "Funding: This work was supported by the British Society for Rheumatology. Acknowledgements: S.S.Z. is supported by a National Institute for Health Research (NIHR) Clinical Lectureship and works in centres supported by Versus Arthritis (grant numbers 21173, 21754 and 21755). H.M.-O. is Chair and Trustee of the British Society for Spondyloarthritis (BRITSpA). H.M.-O. is supported by the NIHR Leeds Biomedical Research Centre (LBRC). The views expressed are those of the authors and not necessarily those of the (UK) National Health Service (NHS), the NIHR or the (UK) Department of Health. {\textcopyright} The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology.",

year = "2023",

month = may,

day = "15",

doi = "10.1093/rap/rkad039",

language = "English",

volume = "7",

journal = "Rheumatology advances in practice",

issn = "2514-1775",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs

T2 - British Society for Rheumatology guideline scope

AU - Zhao, Sizheng Steven

AU - Harrison, Stephanie R

AU - Chan, Antoni

AU - Clarke, Nick

AU - Davis, Charlotte

AU - Eddison, Joe

AU - Gregory, William J

AU - Jones, Gareth T

AU - Marzo-Ortega, Helena

AU - Murphy, Daniel J

AU - Sandhu, Virinderjit

AU - Sengupta, Raj

AU - Siebert, Stefan

AU - Thompson, Ben

AU - Webb, Dale

AU - Yates, Max

AU - Gaffney, Karl

N1 - Funding: This work was supported by the British Society for Rheumatology. Acknowledgements: S.S.Z. is supported by a National Institute for Health Research (NIHR) Clinical Lectureship and works in centres supported by Versus Arthritis (grant numbers 21173, 21754 and 21755). H.M.-O. is Chair and Trustee of the British Society for Spondyloarthritis (BRITSpA). H.M.-O. is supported by the NIHR Leeds Biomedical Research Centre (LBRC). The views expressed are those of the authors and not necessarily those of the (UK) National Health Service (NHS), the NIHR or the (UK) Department of Health. © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology.

PY - 2023/5/15

Y1 - 2023/5/15

N2 - Pharmacological management has advanced considerably since the 2015 British Society for Rheumatology axial spondyloarthritis (axSpA) guideline to incorporate new classes of biologic DMARDs (bDMARDs, including biosimilars), targeted synthetic DMARDs (tsDMARDs) and treatment strategies such as drug tapering. The aim of this guideline is to provide an evidence-based update on pharmacological management of adults with axSpA (including AS and non-radiographic axSpA) using b/tsDMARDs. This guideline is aimed at health-care professionals in the UK who care directly for people with axSpA, including rheumatologists, rheumatology specialist nurses, allied health professionals, rheumatology specialty trainees and pharmacists; people living with axSpA; and other stakeholders, such as patient organizations and charities.

AB - Pharmacological management has advanced considerably since the 2015 British Society for Rheumatology axial spondyloarthritis (axSpA) guideline to incorporate new classes of biologic DMARDs (bDMARDs, including biosimilars), targeted synthetic DMARDs (tsDMARDs) and treatment strategies such as drug tapering. The aim of this guideline is to provide an evidence-based update on pharmacological management of adults with axSpA (including AS and non-radiographic axSpA) using b/tsDMARDs. This guideline is aimed at health-care professionals in the UK who care directly for people with axSpA, including rheumatologists, rheumatology specialist nurses, allied health professionals, rheumatology specialty trainees and pharmacists; people living with axSpA; and other stakeholders, such as patient organizations and charities.

KW - Axial spondyloarthritis

KW - AS

KW - Biologic

KW - Biosimilar

KW - IL17

KW - JAK inhibitor

KW - treat-to-target

KW - switching

KW - tapering

U2 - 10.1093/rap/rkad039

DO - 10.1093/rap/rkad039

M3 - Review article

C2 - 37197377

SN - 2514-1775

VL - 7

JO - Rheumatology advances in practice

JF - Rheumatology advances in practice

IS - 2

M1 - rkad039

ER -

Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope

Abstract

Bibliographical note

Data Availability Statement

Keywords

Access to Document

Fingerprint

Cite this